SK1252001A3 - ANTIOXIDANT, ANTIPROLIFEROUS COMPOSITION, COMPRISING A CARNITINEì (54) AND A CAROTENOID - Google Patents

ANTIOXIDANT, ANTIPROLIFEROUS COMPOSITION, COMPRISING A CARNITINEì (54) AND A CAROTENOID Download PDF

Info

Publication number: SK1252001A3
Authority: SK; Slovakia
Prior art keywords: carnitine; lycopene; composition; propionyl; acid
Prior art date: 1998-08-03

Application number

SK125-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Claudio Cavazza

Original Assignee

Sigma Tau Healthscience Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-03

Filing date

1999-07-29

Publication date

2001-08-06

1999-07-29 Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa

2001-08-06 Publication of SK1252001A3 publication Critical patent/SK1252001A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 61
235000021466 carotenoid Nutrition 0.000 title claims abstract description 30
150000001747 carotenoids Chemical class 0.000 title claims abstract description 29
239000003963 antioxidant agent Substances 0.000 title claims description 7
230000003078 antioxidant effect Effects 0.000 title description 5
UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 85
OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 84
JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 83
235000012661 lycopene Nutrition 0.000 claims abstract description 83
239000001751 lycopene Substances 0.000 claims abstract description 83
229960004999 lycopene Drugs 0.000 claims abstract description 83
ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 83
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims abstract description 49
235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 36
240000003768 Solanum lycopersicum Species 0.000 claims abstract description 34
230000002248 lipoperoxidative effect Effects 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 4
230000001225 therapeutic effect Effects 0.000 claims abstract description 3
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 66
229960004203 carnitine Drugs 0.000 claims description 40
239000000284 extract Substances 0.000 claims description 40
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 16
235000013734 beta-carotene Nutrition 0.000 claims description 16
239000011648 beta-carotene Substances 0.000 claims description 16
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 16
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 16
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 14
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 14
229960002747 betacarotene Drugs 0.000 claims description 14
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 13
ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 11
210000001519 tissue Anatomy 0.000 claims description 10
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 8
230000002062 proliferating effect Effects 0.000 claims description 8
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
208000002177 Cataract Diseases 0.000 claims description 7
230000003143 atherosclerotic effect Effects 0.000 claims description 7
239000001656 lutein Substances 0.000 claims description 7
235000012680 lutein Nutrition 0.000 claims description 7
229960005375 lutein Drugs 0.000 claims description 7
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 7
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 7
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 7
JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 6
QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 6
JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 6
235000003903 alpha-carotene Nutrition 0.000 claims description 6
239000011795 alpha-carotene Substances 0.000 claims description 6
ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 6
235000006708 antioxidants Nutrition 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
239000001775 zeaxanthin Substances 0.000 claims description 6
235000010930 zeaxanthin Nutrition 0.000 claims description 6
229940043269 zeaxanthin Drugs 0.000 claims description 6
201000007737 Retinal degeneration Diseases 0.000 claims description 5
235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 5
230000004258 retinal degeneration Effects 0.000 claims description 5
DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 4
239000004212 Cryptoxanthin Substances 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 4
210000000481 breast Anatomy 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
235000019244 cryptoxanthin Nutrition 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
238000003912 environmental pollution Methods 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
230000002207 retinal effect Effects 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
230000000007 visual effect Effects 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
229940009098 aspartate Drugs 0.000 claims description 3
235000015872 dietary supplement Nutrition 0.000 claims description 3
241000894007 species Species 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
229960005261 aspartic acid Drugs 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
229940001468 citrate Drugs 0.000 claims description 2
229960004106 citric acid Drugs 0.000 claims description 2
239000005515 coenzyme Substances 0.000 claims description 2
239000001530 fumaric acid Substances 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011976 maleic acid Substances 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
235000006408 oxalic acid Nutrition 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
241000227653 Lycopersicon Species 0.000 claims 2
239000000419 plant extract Substances 0.000 claims 2
230000006806 disease prevention Effects 0.000 claims 1
235000005911 diet Nutrition 0.000 abstract description 8
239000004480 active ingredient Substances 0.000 abstract description 2
230000001575 pathological effect Effects 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract description 2
230000004075 alteration Effects 0.000 abstract 1
230000000378 dietary effect Effects 0.000 abstract 1
239000013589 supplement Substances 0.000 abstract 1
238000012360 testing method Methods 0.000 description 18
241000700159 Rattus Species 0.000 description 14
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 13
238000000034 method Methods 0.000 description 12
241001465754 Metazoa Species 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
210000005229 liver cell Anatomy 0.000 description 10
239000000047 product Substances 0.000 description 9
102000052812 Ornithine decarboxylases Human genes 0.000 description 7
108700005126 Ornithine decarboxylases Proteins 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000037213 diet Effects 0.000 description 7
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
241000196324 Embryophyta Species 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
230000003902 lesion Effects 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
PEYTUVXFLCCGCC-YGHSORLUSA-N teleocidin b Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC([C@@](CC[C@]3(C)C=C)(C)C(C)C)=C3C3=C2C1=CN3 PEYTUVXFLCCGCC-YGHSORLUSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
230000009471 action Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
-1 trimethylcyclohexanyl ring Chemical group 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000000260 hypercholesteremic effect Effects 0.000 description 4
238000007689 inspection Methods 0.000 description 4
229940070037 lycopene 5 mg Drugs 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 4
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
108010082126 Alanine transaminase Proteins 0.000 description 3
108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
229950005499 carbon tetrachloride Drugs 0.000 description 3
229930002875 chlorophyll Natural products 0.000 description 3
235000019804 chlorophyll Nutrition 0.000 description 3
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
240000000560 Citrus x paradisi Species 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000021642 Muscular disease Diseases 0.000 description 2
201000009623 Myopathy Diseases 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
235000000719 Prunus africana Nutrition 0.000 description 2
241000200478 Prunus africana Species 0.000 description 2
235000005318 Serenoa repens Nutrition 0.000 description 2
240000006661 Serenoa repens Species 0.000 description 2
108090000992 Transferases Proteins 0.000 description 2
102000004357 Transferases Human genes 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
229940024455 beta carotene 5 mg Drugs 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000004820 blood count Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
150000001746 carotenes Chemical class 0.000 description 2
235000005473 carotenes Nutrition 0.000 description 2
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002380 cytological effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
208000025426 neoplasm of thorax Diseases 0.000 description 2
230000010309 neoplastic transformation Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
201000003957 thoracic cancer Diseases 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
241000202847 Allagoptera arenaria Species 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000219357 Cactaceae Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
235000009467 Carica papaya Nutrition 0.000 description 1
240000006432 Carica papaya Species 0.000 description 1
206010058892 Carnitine deficiency Diseases 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
244000000626 Daucus carota Species 0.000 description 1
235000002767 Daucus carota Nutrition 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108010034791 Heterochromatin Proteins 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
235000004727 Opuntia ficus indica Nutrition 0.000 description 1
240000009297 Opuntia ficus-indica Species 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
241000208292 Solanaceae Species 0.000 description 1
244000300264 Spinacia oleracea Species 0.000 description 1
235000009337 Spinacia oleracea Nutrition 0.000 description 1
240000001717 Vaccinium macrocarpon Species 0.000 description 1
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
208000013521 Visual disease Diseases 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000010208 anthocyanin Nutrition 0.000 description 1
239000004410 anthocyanin Substances 0.000 description 1
229930002877 anthocyanin Natural products 0.000 description 1
150000004636 anthocyanins Chemical class 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000000482 beta-cryptoxanthin group Chemical group 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
235000005487 catechin Nutrition 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000003763 chloroplast Anatomy 0.000 description 1
229950001002 cianidanol Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
235000004634 cranberry Nutrition 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
229940082150 encore Drugs 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
150000002118 epoxides Chemical class 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
230000008821 health effect Effects 0.000 description 1
210000004458 heterochromatin Anatomy 0.000 description 1
235000006486 human diet Nutrition 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229940074551 lutein 5 mg Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000008986 metabolic interaction Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
208000013441 ocular lesion Diseases 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000029553 photosynthesis Effects 0.000 description 1
238000010672 photosynthesis Methods 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
239000011607 retinol Substances 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000005070 ripening Effects 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229960002718 selenomethionine Drugs 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
150000003535 tetraterpenes Chemical class 0.000 description 1
235000009657 tetraterpenes Nutrition 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
235000019160 vitamin B3 Nutrition 0.000 description 1
239000011708 vitamin B3 Substances 0.000 description 1
229940033775 zeaxanthin 1 mg Drugs 0.000 description 1
229940071566 zinc glycinate Drugs 0.000 description 1
UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Natural Medicines & Medicinal Plants (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Botany (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK125-2001A 1998-08-03 1999-07-29 ANTIOXIDANT, ANTIPROLIFEROUS COMPOSITION, COMPRISING A CARNITINEì (54) AND A CAROTENOID SK1252001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT1998RM000516A IT1302125B1 (it)	1998-08-03	1998-08-03	Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
PCT/IT1999/000251 WO2000007581A2 (fr)	1998-08-03	1999-07-29	Composition antioxydante et antiproliferante comprenant une carnitine et un carotenoide

Publications (1)

Publication Number	Publication Date
SK1252001A3 true SK1252001A3 (en)	2001-08-06

Family

ID=11406082

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK125-2001A SK1252001A3 (en)	1998-08-03	1999-07-29	ANTIOXIDANT, ANTIPROLIFEROUS COMPOSITION, COMPRISING A CARNITINEì (54) AND A CAROTENOID

Country Status (21)

Country	Link
EP (1)	EP1102584A2 (fr)
JP (1)	JP2002522382A (fr)
KR (1)	KR20010072146A (fr)
CN (1)	CN1311674A (fr)
AR (1)	AR021172A1 (fr)
AU (1)	AU5064199A (fr)
BR (1)	BR9912703A (fr)
CA (1)	CA2338035A1 (fr)
EE (1)	EE200100052A (fr)
HK (1)	HK1039062A1 (fr)
HU (1)	HUP0102807A2 (fr)
IL (1)	IL140797A0 (fr)
IS (1)	IS5816A (fr)
IT (1)	IT1302125B1 (fr)
MA (1)	MA26666A1 (fr)
NO (1)	NO20010532L (fr)
PL (1)	PL346161A1 (fr)
SK (1)	SK1252001A3 (fr)
TN (1)	TNSN99152A1 (fr)
TR (1)	TR200100333T2 (fr)
WO (1)	WO2000007581A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1286704T3 (da)	2000-06-02	2014-09-22	Univ Texas	Ethylendicystein (EC)-glucose analoge konjugater
US6923960B2 (en)	2001-10-03	2005-08-02	Vsl Pharmaceuticals Inc.	Antioxidant combination composition and use thereof
KR100523562B1 (ko)	2001-10-29	2005-10-25	한국과학기술연구원	손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
JP4527938B2 (ja) *	2002-07-23	2010-08-18	オルビス株式会社	抗酸化用の経口投与組成物
JP4334189B2 (ja) *	2002-07-30	2009-09-30	カゴメ株式会社	Ａｇｅ生成阻害剤
ITRM20020620A1 (it) *	2002-12-13	2004-06-14	Sigma Tau Ind Farmaceuti	Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
JP4369924B2 (ja)	2003-04-14	2009-11-25	日本曹達株式会社	ジアミン誘導体、製造法及び抗酸化薬
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
EP1711070B1 (fr) *	2004-01-28	2015-12-09	Nestec S.A.	Composition nutritionnelle conçue pour ameliorer l'etat de la peau et prevenir des maladies de la peau
US8758723B2 (en)	2006-04-19	2014-06-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for cellular imaging and therapy
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
RU2619342C1 (ru) *	2016-02-24	2017-05-15	федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет"	Препарат для профилактики и лечения свободнорадикальной патологии у животных
CN113491687A (zh) *	2020-04-02	2021-10-12	常州高新技术产业开发区三维工业技术研究所有限公司	一种解毒药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU518617B2 (en) *	1977-04-29	1981-10-08	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Therapeutic application of acetyl-d, 1-carnitine
EP0400547A1 (fr) *	1989-06-02	1990-12-05	Abbott Laboratories	Produit de nutrition parentéral
IT1276225B1 (it) *	1995-10-17	1997-10-27	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283967B1 (it) *	1996-03-29	1998-05-07	Sigma Tau Ind Farmaceuti	Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5667791A (en) *	1996-05-31	1997-09-16	Thione International, Inc.	X-ray induced skin damage protective composition
US5895652A (en) *	1996-07-29	1999-04-20	Longevity Institute International	Method of metabolic adjuvanation and cellular repair
CA2280093A1 (fr) *	1997-02-04	1998-08-06	John V. Kosbab	Compositions et procedes destines a la prevention et au traitement de maladies degeneratives vasculaires
IT1291113B1 (it) *	1997-03-20	1998-12-29	Sigma Tau Ind Farmaceuti	Composizione nutritiva terapeutica per soggetti affetti da diabete mellito

1998
- 1998-08-03 IT IT1998RM000516A patent/IT1302125B1/it active IP Right Grant
1999
- 1999-07-29 TR TR2001/00333T patent/TR200100333T2/xx unknown
- 1999-07-29 BR BR9912703-2A patent/BR9912703A/pt not_active Application Discontinuation
- 1999-07-29 EP EP99935044A patent/EP1102584A2/fr not_active Withdrawn
- 1999-07-29 CN CN99809268A patent/CN1311674A/zh active Pending
- 1999-07-29 EE EEP200100052A patent/EE200100052A/xx unknown
- 1999-07-29 KR KR1020017001339A patent/KR20010072146A/ko not_active Withdrawn
- 1999-07-29 SK SK125-2001A patent/SK1252001A3/sk unknown
- 1999-07-29 HU HU0102807A patent/HUP0102807A2/hu unknown
- 1999-07-29 AU AU50641/99A patent/AU5064199A/en not_active Abandoned
- 1999-07-29 CA CA002338035A patent/CA2338035A1/fr not_active Abandoned
- 1999-07-29 WO PCT/IT1999/000251 patent/WO2000007581A2/fr not_active Ceased
- 1999-07-29 PL PL99346161A patent/PL346161A1/xx unknown
- 1999-07-29 HK HK02100334.3A patent/HK1039062A1/zh unknown
- 1999-07-29 IL IL14079799A patent/IL140797A0/xx unknown
- 1999-07-29 JP JP2000563266A patent/JP2002522382A/ja active Pending
- 1999-07-30 TN TNTNSN99152A patent/TNSN99152A1/fr unknown
- 1999-08-03 MA MA25710A patent/MA26666A1/fr unknown
- 1999-08-03 AR ARP990103863A patent/AR021172A1/es unknown
2001
- 2001-01-16 IS IS5816A patent/IS5816A/is unknown
- 2001-01-31 NO NO20010532A patent/NO20010532L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20010532D0 (no)	2001-01-31
KR20010072146A (ko)	2001-07-31
IT1302125B1 (it)	2000-07-31
CA2338035A1 (fr)	2000-02-17
MA26666A1 (fr)	2004-12-20
JP2002522382A (ja)	2002-07-23
IS5816A (is)	2001-01-16
WO2000007581A2 (fr)	2000-02-17
PL346161A1 (en)	2002-01-28
AU5064199A (en)	2000-02-28
ITRM980516A0 (it)	1998-08-03
BR9912703A (pt)	2001-05-02
EP1102584A2 (fr)	2001-05-30
ITRM980516A1 (it)	2000-02-03
CN1311674A (zh)	2001-09-05
HUP0102807A2 (hu)	2002-03-28
EE200100052A (et)	2002-06-17
HK1039062A1 (zh)	2002-04-12
TNSN99152A1 (fr)	2005-11-10
IL140797A0 (en)	2002-02-10
AR021172A1 (es)	2002-07-03
TR200100333T2 (tr)	2001-07-23
WO2000007581A3 (fr)	2000-05-11
NO20010532L (no)	2001-03-20

Publication	Publication Date	Title
Walingo	2005	Role of vitamin C (ascorbic acid) on human health-a review
EP0973532B1 (fr)	2005-09-07	Preparations anti-proliferatives
JP4166951B2 (ja)	2008-10-15	脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
DE60015893T2 (de)	2005-12-01	Zusammensetzung enthaltend ein carnitine und glutathion, zur erhöhung der absorption von glutathion und zur synergisierung seiner effekte
AU6141498A (en)	1998-08-25	Compositions and methods for prevention and treatment of vascular degenerative diseases
Lawlor et al.	1995	Astaxanthin: antioxidant effects in chicken embryo fibroblasts
CA2521149C (fr)	2014-03-25	Compositions d'extrait de rocou contenant des geranylgeraniols et modes d'utilisation
EP1102584A2 (fr)	2001-05-30	Composition antioxydante et antiproliferante comprenant une carnitine et un carotenoide
Sarialtin et al.	2018	An overview on the role of macular xanthophylls in ocular diseases
KR100530878B1 (ko)	2005-11-23	Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 및 긴 사슬의알카놀을 함유하는 조성물
US20080027139A1 (en)	2008-01-31	Use of Alpha-Ketoglutarate and Related Compounds
US10568846B2 (en)	2020-02-25	Betacryptoxanthin compositions, processes for preparation and uses thereof
CZ200197A3 (cs)	2001-07-11	Antioxidační a antiproliferační přípravek obsahující karnitin a karotenoid
Mohammad et al.	2021	Antioxidant effects of resistance training with pumpkin seed extract consumption in heart tissue of rats exposed to H2O2-induced oxidative damage
AU762968B2 (en)	2003-07-10	Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
MXPA01000874A (en)	2002-03-26	Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
Iheagwam et al.	2024	Sustainable Role of Terminalia catappa Extract for Maintaining Antioxidant Activities in Wistar Rats
Peyravi et al.	2016	The protective effects of vitamins C and E on the oxidative stress induced by sodium metabisulfite on the kidney tissue in adult rats
Elhassaneen et al.	2024	Dietary Intervention using Reishi Mushroom (Ganoderma Lucidum) Reduces Oxidative Stress and Enhances Erythrocyte/Serum Defense Systems in Alloxan-Induced Diabetic Rats
US20120172450A1 (en)	2012-07-05	Use of jasmonate for improving skeletal muscle function
Mahboob et al.	0	ANTI-OXIDANT AND THERAPEUTIC PROPERTIES OF POMEGRANATE FOR HEALTH BENEFITS